---
title: "Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection: Indication questions"
description: "Indication questions on Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Drug names. Questions: What is Biktarvy approved for? What is the generic name for Biktarvy? Can Biktarvy be used in people with prior HIV treatment who are not virologically suppressed? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/indication"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection: Indication questions

Manufacturer: Gilead Sciences, Inc.  
Prescribing information: [Biktarvy](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf)

## Indication

<a id="biktarvy-indication"></a>

### What is Biktarvy approved for?

> “BIKTARVY® is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing ≥14 kg with no antiretroviral (ARV) treatment history; or with an ARV treatment history and not virologically suppressed, with no known or suspected substitutions associated with resistance to the integrase strand inhibitor class, emtricitabine, or tenofovir; or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable ARV regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir.”

Source: [BIKTARVY: Important Safety Information, captured 2026-11-12](https://www.biktarvyhcp.com/important-safety-information#:~:text=BIKTARVY%C2%AE%20is%20indicated%20as%20a,resistance%20to%20bictegravir%20or%20tenofovir.)

<a id="biktarvy-treatment-experienced-not-suppressed"></a>

### Can Biktarvy be used in people with prior HIV treatment who are not virologically suppressed?

> “Use of BIKTARVY in those with an antiretroviral treatment history and not virologically 
> suppressed is supported by a scientific rationale that this population is expected to have 
> similar virologic response rates to those with no history of antiretroviral treatment 
> provided that the virus is susceptible to the individual components of the 
> regimen. Because limited clinical trial data are available supporting the efficacy of 
> BIKTARVY in patients with baseline INSTI resistance substitutions, this indication states 
> use in individuals with an antiretroviral treatment history and who are not virologically 
> suppressed with no evidence of known or suspected substitutions associated with”

Source: [BIKTARVY: Prescribing information, page 37, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=37)

> “resistance to the INSTI class, rather than only to bictegravir. Additionally, this indication 
> states the individuals should have no known or suspected substitutions associated with 
> resistance to emtricitabine, or tenofovir [see Clinical Studies (14.2 and 14.5)].”

Source: [BIKTARVY: Prescribing information, page 38, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=38)

## Drug names

<a id="biktarvy-generic-name"></a>

### What is the generic name for Biktarvy?

> “BIKTARVY<sup>®</sup> (bictegravir, emtricitabine, and tenofovir alafenamide) 
> tablets, for oral use”

Source: [BIKTARVY: Prescribing information, page 1, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=1)

## Related pages
- [Medical information: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide): HIV-1 infection](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection)
- [Pharmacology](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/safety)
- [Specific populations](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/guidelines)
